A Phase 1 Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Latest Information Update: 01 Jun 2025
At a glance
- Drugs Azacitidine (Primary) ; Revumenib (Primary) ; Venetoclax (Primary) ; Cytarabine; Methotrexate
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Acronyms BEAT-AML
Most Recent Events
- 14 May 2025 According to a Syndax Pharmaceuticals media release, data from this study will be presented at the 30th European Hematology Association (EHA) Annual Congress Meeting being held June 12-15, 2025, in Milan, Italy.
- 05 May 2025 According to a Syndax Pharmaceuticals media release, company anticipates that an update on the trial will be available at a medical meeting in the second quarter of 2025.
- 09 Dec 2024 According to a Syndax Pharmaceuticals media release, announced additional positive data from BEAT AML trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed AML patients.